Medical inquiries

Connect with my medical science liaison

Chat live

Available Monday - Friday 9AM - 4:30PM ET

Call me now

Available Monday - Friday 9AM - 7:30PM ET

Email your inquiry

Call 1-800-526-7736

Available Monday - Friday 9AM - 8PM ET

Live video

Available Monday - Friday 9AM - 4:30PM ET

This information is intended for US healthcare professionals to access current scientific information about J&J Innovative Medicine products. It is prepared by Medical Information and is not intended for promotional purposes, nor to provide medical advice.

TREMFYA® (guselkumab)

Medical Information

TREMFYA - Retreatment of Crohn’s Disease after a Drug Free Interval

Last Updated: 06/17/2025

SUMMARY

The company cannot recommend any practices, procedures, or usage that deviate from the approved labeling.
The phase 3 clinical trial program of TREMFYA in the treatment of adults with moderately to severely active Crohn’s disease did not evaluate retreatment with TREMFYA after a drug free interval.¹^,²

LITERATURE SEARCH

A literature search of MEDLINE^®, EMBASE^®, BIOSIS Previews^®, and DERWENT^® (and/or other resources, including internal/external databases) was conducted on 16 June 2025.

References

Show

1	Janssen Research & Development, LLC. A study of the efficacy and safety of guselkumab in participants with moderately to severely active Crohn’s disease (GALAXI). In: Clinical Trials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 April 25]. Available from: https://clinicaltrials.gov/ct2/show/NCT03466411 NLM Identifier: NCT03466411.
2	Janssen Research and Development, LLC. A study of guselkumab subcutaneous therapy in participants with moderately to severely active Crohn’s disease (GRAVITI). In: ClinicalTrials.gov [Internet]. Bethesda (MD): National Library of Medicine (US). 2000- [cited 2025 June 16]. Available from: https://clinicaltrials.gov/study/NCT05197049 NLM Identifier: NCT05197049.

Endchat

Chat live